A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

Project: Other project

StatusActive
Effective start/end date4/17/173/1/20

Funding

  • Amgen Inc: $10,223.08